Inhaled anticholinergic drugs and risk of acute urinary retention

BJU International

Volumn 107, Issue 8, 2011, Pages 1265-1272

  Afonso, Ana S M ^a   Verhamme, Katia M C ^a   Stricker, Bruno H C ^a   Sturkenboom, Miriam C J M ^a   Brusselle, Guy G O ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

acute urinary retention; benign prostatic hyperplasia; case control study; chronic obstructive pulmonary disease; cohort; inhaled anticholinergic drugs

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; SCOPOLAMINE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRY POWDER; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; METERED DOSE INHALER; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; URINE RETENTION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MICTURITION; MIDDLE AGED; MULTICENTER STUDY; NEBULIZER; NETHERLANDS; PATHOPHYSIOLOGY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR;

ACUTE DISEASE; ADMINISTRATION, INHALATION; AGED; CHOLINERGIC ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NETHERLANDS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; SCOPOLAMINE DERIVATIVES; SEX FACTORS; URINARY RETENTION; URINATION;

EID: 79954486779     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09600.x     Document Type: Article

References (35)

1. Burney P, Suissa S, Soriano JB, et al,. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J Suppl 2003; 43: 1s-44s
2. Rabe KF, Hurd S, Anzueto A, et al,. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55 (Pubitemid 47403272)
3. Restrepo RD,. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007; 52: 833-51
4. Armitage JN, Sibanda N, Cathcart PJ, Emberton M, van der Meulen JH,. Mortality in men admitted to hospital with acute urinary retention: database analysis. BMJ 2007; 335: 1199-202 (Pubitemid 350273304)
5. Verhamme KM, Dieleman JP, Van Wijk MA, et al,. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med 2005; 165: 1547-51 (Pubitemid 41058037)
6. Appleton S, Jones T, Poole P, et al,. Ipratropium bromide versus the long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101
7. Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, Roehrborn CG,. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009; 182: 1442-8
8. Gross NJ,. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006; 533: 36-9 (Pubitemid 43340003)
9. Pras E, Steinlauf S, Pinkhas J, Sidi Y,. Urinary retention associated with ipratropium bromide. DICP 1991; 25: 939-40
10. Lozewicz S,. Bladder outflow obstruction induced by ipratropium bromide. Postgrad Med J 1989; 65: 260-1 (Pubitemid 19097184)
11. Barr RG, Bourbeau J, Camargo CA, Ram FS,. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-62 (Pubitemid 44570305)
12. Pedone C, Incalzi RA,. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 185
13. van der Lei J, Duisterhout JS, Westerhof HP, et al,. The introduction to the computer-based patients records in the Netherlands. Ann Intern Med 1993; 119: 1036-41 (Pubitemid 23334661)
14. Sturkenboom MC,. The pharmacoepidemiology of COPD: recent advances and methodological discussion. The Integrated Primary Care Information experience in COPD in the Netherlands. Eur Respir J 2003; 22: 34s-7s
15. Lamberts H, Wood M, Hofmans-Okkes IM,. International Primary Care Classifications: the effect of fifteen years of evolution. Fam Pract 1992; 9: 330-9
16. World Health Organization (WHO). Anatomical Therapeutic Chemical (ATC) Index with Defined Daily Dosages. Oslo, Norway: WHO Collaborating Center for Drug Statistics Methodology, 2002
17. Vlug AE, van der Lei J, Mossevel BM, et al,. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999; 38: 339-44 (Pubitemid 30030067)
18. Hofmans-Okkes IM, Lamberts H,. The International Classification of Primary Care (ICPC): new applications in research and computer-based patient records in family practice. Fam Pract 1996; 13: 294-302 (Pubitemid 26229398)
19. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R,. Drug-inducer urinary retention: incidence, management and prevention. Drug Saf 2008; 31: 373-88 (Pubitemid 351563730)
20. Wu J, Baguley IJ,. Urinary retention in a general rehabilitation unit: prevalence, clinical outcome, and the role of screening. Arch Phys Med Rehabil 2005; 86: 1772-7 (Pubitemid 41354189)
21. Ernst P, Gonzalez A, Brassard P, Suissa S,. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-6 (Pubitemid 47057852)
22. Maldonado G, Greenland S,. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-36 (Pubitemid 24002359)
23. Kesten S, Jara M, Wentworth C, Lanes S,. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130: 1695-703 (Pubitemid 46033421)
24. Vucicevic Boras V, Savage N, Mohamad Zaini Z,. Oral aphthous-like ulceration due to tiotropium bromide. Med Oral Patol Oral Cir Bucal 2007; 12: E209-10
25. Vincken W, van Noord JA, Greefhorst AP, et al,. Improved health outcomes in patients with COPD during 1 yr's treatment with toptropium. Eur Respir J 2002; 19: 209-16 (Pubitemid 34162819)
26. Hess DR, Dillman C, Kacmarek RM,. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive Care Med 2003; 29: 1145-50 (Pubitemid 36918559)
27. Duarte AG,. Inhaled bronchodilator administration during mechanical ventilation. Respir Care 2004; 49: 623-34
28. Olin JL,. Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease. Am J Health Syst Pharm 2005; 62: 1263-9 (Pubitemid 40840065)
29. Kelly WH,. Pharmacotherapy update. The metered-dose inhaler plus spacer versus nebulizer debate, or I recently met an analysis with which I disagreed. Pediatr Asthma Allergy Immunol 2006; 19: 63-6
30. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D,. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62
31. Chapple C,. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 43-8
32. Novara G, Galfano A, Secco S, et al,. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008; 54: 740-63
33. Roehrborn CG,. BPH progression. concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008; 101 (Suppl. 3): 17-21 (Pubitemid 351328802)
34. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
35. Roehrborn CG, Siami P, Barkin J, et al,. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Euro Urol 2010; 57: 123-31